Leading US biotech Bluebird eyes UK launch for pioneering gene therapies – Telegraph.co.uk
Telegraph.co.uk |
Leading US biotech Bluebird eyes UK launch for pioneering gene therapies
Telegraph.co.uk One of America's leading biotechs, Bluebird Bio, is in talks with UK medicine regulators about a potential launch of its pioneering range of gene therapies for rare diseases. Bluebird has a market value of over $4bn (£3bn) on New York's Nasdaq stock … |
